Status:

WITHDRAWN

Corneal Crosslinking in Keratoconus and Corneal Ectasia

Lead Sponsor:

Ohio State University

Conditions:

Progressive Keratoconus

Corneal Ectasia

Eligibility:

All Genders

18+ years

Phase:

PHASE2

PHASE3

Brief Summary

Prospective, randomized, single site to determine the safety and effectiveness of performing corneal collagen cross-linking (CXL) using riboflavin and UVA light in eyes progressive keratoconus or corn...

Detailed Description

After epithelial surface removal riboflavin drops are applied until there is saturation of the cornea.Then the UVA light is turned on to active the crosslinking process while drops are continued for t...

Eligibility Criteria

Inclusion

  • Diagnosis of keratoconus with documented progression over the previous 12 months.
  • Diagnosis of corneal ectasia
  • Must be able to complete all study visits.

Exclusion

  • Prior corneal surgery in keratoconus group
  • Corneal scarring
  • Pregnancy

Key Trial Info

Start Date :

April 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2010

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT00679666

Start Date

April 1 2008

End Date

October 1 2010

Last Update

April 20 2017

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

The Ohio State University Medical Center

Columbus, Ohio, United States, 43210

2

OSU Havener Eye Institute

Dublin, Ohio, United States, 43016